JPWO2022103852A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022103852A5 JPWO2022103852A5 JP2023528056A JP2023528056A JPWO2022103852A5 JP WO2022103852 A5 JPWO2022103852 A5 JP WO2022103852A5 JP 2023528056 A JP2023528056 A JP 2023528056A JP 2023528056 A JP2023528056 A JP 2023528056A JP WO2022103852 A5 JPWO2022103852 A5 JP WO2022103852A5
- Authority
- JP
- Japan
- Prior art keywords
- rna
- target
- editing
- guide
- positions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020005004 Guide RNA Proteins 0.000 claims description 295
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 217
- 239000002773 nucleotide Substances 0.000 claims description 161
- 125000003729 nucleotide group Chemical group 0.000 claims description 161
- 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 claims description 132
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 claims description 132
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 claims description 105
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 claims description 96
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 claims description 67
- 230000008685 targeting Effects 0.000 claims description 56
- 239000013598 vector Substances 0.000 claims description 43
- 239000000758 substrate Substances 0.000 claims description 38
- 102000040430 polynucleotide Human genes 0.000 claims description 34
- 108091033319 polynucleotide Proteins 0.000 claims description 34
- 239000002157 polynucleotide Substances 0.000 claims description 34
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims description 29
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 23
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 20
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 20
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 20
- 208000012902 Nervous system disease Diseases 0.000 claims description 17
- 208000025966 Neurological disease Diseases 0.000 claims description 17
- 108020004999 messenger RNA Proteins 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 229960005305 adenosine Drugs 0.000 claims description 10
- 229940104302 cytosine Drugs 0.000 claims description 10
- 238000009396 hybridization Methods 0.000 claims description 8
- 239000013607 AAV vector Substances 0.000 claims description 7
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 7
- 208000027073 Stargardt disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 5
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 5
- 108091023045 Untranslated Region Proteins 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000034799 Tauopathies Diseases 0.000 claims description 4
- -1 carrier Substances 0.000 claims description 4
- 102000043770 human ADAR Human genes 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 claims description 3
- 102100040243 Microtubule-associated protein tau Human genes 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 2
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 2
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 2
- 241000649046 Adeno-associated virus 11 Species 0.000 claims description 2
- 241000649047 Adeno-associated virus 12 Species 0.000 claims description 2
- 241000300529 Adeno-associated virus 13 Species 0.000 claims description 2
- 241000958487 Adeno-associated virus 3B Species 0.000 claims description 2
- 102000055025 Adenosine deaminases Human genes 0.000 claims description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 102100035426 DnaJ homolog subfamily B member 7 Human genes 0.000 claims description 2
- 102100024692 Double-stranded RNA-specific editase B2 Human genes 0.000 claims description 2
- 101100285903 Drosophila melanogaster Hsc70-2 gene Proteins 0.000 claims description 2
- 101100178718 Drosophila melanogaster Hsc70-4 gene Proteins 0.000 claims description 2
- 101100178723 Drosophila melanogaster Hsc70-5 gene Proteins 0.000 claims description 2
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 claims description 2
- 101000804114 Homo sapiens DnaJ homolog subfamily B member 7 Proteins 0.000 claims description 2
- 101000686486 Homo sapiens Double-stranded RNA-specific editase B2 Proteins 0.000 claims description 2
- 101001004953 Homo sapiens Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 claims description 2
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 claims description 2
- 101000836983 Homo sapiens Secretoglobin family 1D member 1 Proteins 0.000 claims description 2
- 101150090950 Hsc70-1 gene Proteins 0.000 claims description 2
- 101150110423 SNCA gene Proteins 0.000 claims description 2
- 101100150366 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sks2 gene Proteins 0.000 claims description 2
- 108091026823 U7 small nuclear RNA Proteins 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 claims 2
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 claims 2
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 claims 2
- 101100077717 Mus musculus Morn2 gene Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 238000010357 RNA editing Methods 0.000 description 198
- 230000026279 RNA modification Effects 0.000 description 198
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 description 65
- 238000013461 design Methods 0.000 description 47
- 238000012163 sequencing technique Methods 0.000 description 42
- 238000010586 diagram Methods 0.000 description 33
- 238000000034 method Methods 0.000 description 30
- 230000035772 mutation Effects 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 19
- 239000003086 colorant Substances 0.000 description 14
- 108700019024 Drosophila Adar Proteins 0.000 description 8
- 102200092160 rs34637584 Human genes 0.000 description 8
- 238000007423 screening assay Methods 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 7
- 208000019423 liver disease Diseases 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 229930024421 Adenine Natural products 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- 229960000643 adenine Drugs 0.000 description 6
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 6
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102220003686 rs137852449 Human genes 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000002780 macular degeneration Diseases 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000007480 sanger sequencing Methods 0.000 description 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 101150039555 ABCA4 gene Proteins 0.000 description 3
- 108090000185 alpha-Synuclein Proteins 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 101150069374 Serpina1 gene Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000005221 acidic domain Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 230000004576 lipid-binding Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 102200036624 rs104893875 Human genes 0.000 description 2
- 102200036626 rs104893877 Human genes 0.000 description 2
- 102200036620 rs104893878 Human genes 0.000 description 2
- 102200092237 rs10878307 Human genes 0.000 description 2
- 102200092229 rs111341148 Human genes 0.000 description 2
- 102220010570 rs111501952 Human genes 0.000 description 2
- 102220010583 rs111910483 Human genes 0.000 description 2
- 102220010533 rs113065049 Human genes 0.000 description 2
- 102220010573 rs113431708 Human genes 0.000 description 2
- 102200092153 rs113511708 Human genes 0.000 description 2
- 102220010563 rs113589830 Human genes 0.000 description 2
- 102200092166 rs11564148 Human genes 0.000 description 2
- 102200058742 rs121909568 Human genes 0.000 description 2
- 102200013794 rs121918339 Human genes 0.000 description 2
- 102200092162 rs145364431 Human genes 0.000 description 2
- 102200092169 rs145364431 Human genes 0.000 description 2
- 102200092228 rs17466213 Human genes 0.000 description 2
- 102200092151 rs201271001 Human genes 0.000 description 2
- 102220010535 rs202009639 Human genes 0.000 description 2
- 102200092236 rs281865043 Human genes 0.000 description 2
- 102200092233 rs281865044 Human genes 0.000 description 2
- 102200092234 rs281865045 Human genes 0.000 description 2
- 102220010555 rs281865046 Human genes 0.000 description 2
- 102220010556 rs281865047 Human genes 0.000 description 2
- 102220010568 rs281865048 Human genes 0.000 description 2
- 102220010572 rs281865050 Human genes 0.000 description 2
- 102220010576 rs281865051 Human genes 0.000 description 2
- 102200092164 rs281865053 Human genes 0.000 description 2
- 102200092304 rs281865057 Human genes 0.000 description 2
- 102200092172 rs33949390 Human genes 0.000 description 2
- 102200092218 rs33958906 Human genes 0.000 description 2
- 102200092156 rs33995883 Human genes 0.000 description 2
- 102200092238 rs34410987 Human genes 0.000 description 2
- 102200092154 rs34778348 Human genes 0.000 description 2
- 102200092231 rs34805604 Human genes 0.000 description 2
- 102200092216 rs34995376 Human genes 0.000 description 2
- 102200092239 rs35173587 Human genes 0.000 description 2
- 102200092170 rs35303786 Human genes 0.000 description 2
- 102200092217 rs35507033 Human genes 0.000 description 2
- 102200092163 rs35602796 Human genes 0.000 description 2
- 102220010596 rs35658131 Human genes 0.000 description 2
- 102200092167 rs35801418 Human genes 0.000 description 2
- 102200015429 rs36084898 Human genes 0.000 description 2
- 102200092303 rs3761863 Human genes 0.000 description 2
- 102200092226 rs4640000 Human genes 0.000 description 2
- 102200092173 rs56108242 Human genes 0.000 description 2
- 102200106842 rs573916965 Human genes 0.000 description 2
- 102220010546 rs58559150 Human genes 0.000 description 2
- 102200092232 rs60185966 Human genes 0.000 description 2
- 102200004723 rs60440396 Human genes 0.000 description 2
- 102200092221 rs7133914 Human genes 0.000 description 2
- 102220010557 rs72546324 Human genes 0.000 description 2
- 102220010562 rs72546327 Human genes 0.000 description 2
- 102220010536 rs72546335 Human genes 0.000 description 2
- 102220010544 rs72546337 Human genes 0.000 description 2
- 102220010561 rs72546338 Human genes 0.000 description 2
- 102200092175 rs7308720 Human genes 0.000 description 2
- 102220010554 rs74985840 Human genes 0.000 description 2
- 102200092230 rs76535406 Human genes 0.000 description 2
- 102220010552 rs78365431 Human genes 0.000 description 2
- 102200092302 rs78964014 Human genes 0.000 description 2
- 102220010599 rs79546190 Human genes 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000016871 Hexosaminidase A Human genes 0.000 description 1
- 108010053317 Hexosaminidase A Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 102200092158 rs111691891 Human genes 0.000 description 1
- 102220010587 rs281865052 Human genes 0.000 description 1
- 102220010589 rs281865055 Human genes 0.000 description 1
- 102200092159 rs34015634 Human genes 0.000 description 1
- 102200092155 rs35870237 Human genes 0.000 description 1
- 102200031910 rs587777453 Human genes 0.000 description 1
- 102220010569 rs74681492 Human genes 0.000 description 1
- 102200092161 rs77428810 Human genes 0.000 description 1
- 102220010590 rs78029637 Human genes 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112452P | 2020-11-11 | 2020-11-11 | |
| US63/112,452 | 2020-11-11 | ||
| US202063119754P | 2020-12-01 | 2020-12-01 | |
| US63/119,754 | 2020-12-01 | ||
| US202163153070P | 2021-02-24 | 2021-02-24 | |
| US63/153,070 | 2021-02-24 | ||
| US202163178159P | 2021-04-22 | 2021-04-22 | |
| US63/178,159 | 2021-04-22 | ||
| US202163193373P | 2021-05-26 | 2021-05-26 | |
| US63/193,373 | 2021-05-26 | ||
| PCT/US2021/058799 WO2022103852A1 (en) | 2020-11-11 | 2021-11-10 | Rna-editing compositions and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024500279A JP2024500279A (ja) | 2024-01-09 |
| JP2024500279A5 JP2024500279A5 (https=) | 2024-11-18 |
| JPWO2022103852A5 true JPWO2022103852A5 (https=) | 2024-11-18 |
Family
ID=81601658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528056A Pending JP2024500279A (ja) | 2020-11-11 | 2021-11-10 | Ｒｎａ編集組成物及び使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230399635A1 (https=) |
| EP (1) | EP4244358A4 (https=) |
| JP (1) | JP2024500279A (https=) |
| AU (1) | AU2021378789A1 (https=) |
| CA (1) | CA3174139A1 (https=) |
| WO (1) | WO2022103852A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| US10941402B2 (en) | 2016-09-01 | 2021-03-09 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded RNA-editing oligonucleotides |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| AU2022301997A1 (en) * | 2021-06-29 | 2024-01-04 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides |
| EP4441219A2 (en) * | 2021-12-01 | 2024-10-09 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides for rna editing targeting lrrk2 |
| US20250154504A1 (en) | 2022-02-14 | 2025-05-15 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| EP4555086A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| JP2025525564A (ja) * | 2022-07-18 | 2025-08-05 | エフ． ホフマン－ラ ロシュ アーゲー | オリゴヌクレオチドの編集 |
| JP2025525583A (ja) | 2022-07-19 | 2025-08-05 | ランパート バイオサイエンス インコーポレイテッド | 非免疫原性環状非ウイルス性ｄｎａベクター |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| AR131145A1 (es) | 2022-11-24 | 2025-02-19 | Proqr Therapeutics Ii Bv | Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| CA3276262A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2024137991A2 (en) * | 2022-12-23 | 2024-06-27 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| EP4669753A1 (en) | 2023-02-20 | 2025-12-31 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| WO2024206175A1 (en) | 2023-03-24 | 2024-10-03 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| AU2024246572A1 (en) | 2023-03-27 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2024226860A2 (en) * | 2023-04-26 | 2024-10-31 | Shape Therapeutics Inc. | Small nuclear rna processing hairpins for small rna payloads |
| WO2024256620A1 (en) | 2023-06-16 | 2024-12-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
| WO2025015091A1 (en) * | 2023-07-11 | 2025-01-16 | Shape Therapeutics Inc. | Serpina1-targeting engineered guide rnas and polynucleotides |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| WO2026006476A1 (en) * | 2024-06-25 | 2026-01-02 | Shape Therapeutics Inc. | Abca4 vectors and engineered guide rnas |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3475424A1 (en) * | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| EP4389889A3 (en) * | 2017-10-06 | 2024-09-04 | Oregon Health & Science University | Compositions and methods for editing rna |
| AU2019336793B2 (en) * | 2018-09-06 | 2024-11-21 | The Regents Of The University Of California | RNA and DNA base editing via engineered ADAR recruitment |
| WO2021113270A1 (en) * | 2019-12-02 | 2021-06-10 | Shape Therapeutics Inc. | Therapeutic editing |
| CN115777020A (zh) * | 2020-04-22 | 2023-03-10 | 塑造治疗公司 | 使用snrna组分的组合物和方法 |
-
2021
- 2021-11-10 WO PCT/US2021/058799 patent/WO2022103852A1/en not_active Ceased
- 2021-11-10 EP EP21892738.2A patent/EP4244358A4/en active Pending
- 2021-11-10 JP JP2023528056A patent/JP2024500279A/ja active Pending
- 2021-11-10 US US18/036,176 patent/US20230399635A1/en active Pending
- 2021-11-10 CA CA3174139A patent/CA3174139A1/en active Pending
- 2021-11-10 AU AU2021378789A patent/AU2021378789A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022103852A5 (https=) | ||
| JP2023523237A (ja) | ｓｎＲＮＡ構成要素を使用する組成物及び方法 | |
| GB2590880A (en) | RNA and DNA base editing via engineered ADAR recruitment | |
| US20260034247A1 (en) | Compositions and methods for treating cep290-associated disease | |
| EP4555085A1 (en) | Chemically modified oligonucleotides for adar-mediated rna editing | |
| US20230295725A1 (en) | Compositions and methods for treating cep290-associated disease | |
| US20060234247A1 (en) | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing | |
| EP3374494A1 (en) | Crispr compositions and methods of using the same for gene therapy | |
| JP2024123226A (ja) | 肝特異的ウイルスプロモーター及びその使用方法 | |
| EP3116997A1 (en) | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) | |
| JPWO2021242903A5 (https=) | ||
| JP2022541070A (ja) | 調節可能な発現系 | |
| JP2024543000A (ja) | 操作されたｒｎａ | |
| WO2020027982A1 (en) | Compositions and methods for treating cep290-associated disease | |
| Minskaia et al. | Viral vectors in gene replacement therapy | |
| US20210355488A1 (en) | Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas Effector Enzymes | |
| CA3232641A1 (en) | Liver-specific expression cassettes, vectors and uses thereof for expressing therapeutic proteins | |
| JPWO2020176552A5 (https=) | ||
| Stamataki et al. | Identification of AAV variants with improved transduction of human vascular endothelial cells by screening AAV capsid libraries in non-human primates | |
| EP4601710A2 (en) | Engineered nucleic acid regulatory elements and methods and uses thereof | |
| EP4423274A2 (en) | Rna-editing compositions and methods of use | |
| WO2025006957A2 (en) | Non-neutralizing aav constructs and methods of generating and using same | |
| WO2025015091A1 (en) | Serpina1-targeting engineered guide rnas and polynucleotides | |
| JP2024543208A (ja) | Ｌｒｒｋ２を標的としたｒｎａ編集のための遺伝子操作されたガイドｒｎａ及びポリヌクレオチド | |
| CN118434862A (zh) | Rna编辑组合物和使用方法 |